FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2020681444> ?p ?o ?g. }

• W2020681444 endingPage "33" @default.
• W2020681444 startingPage "23" @default.
• W2020681444 abstract "Fabry disease is an X-linked lysosomal storage disorder caused by a deficiency in α-galactosidase A (α-Gal A) activity and subsequent accumulation of the substrate globotriaosylceramide (GL-3), which contributes to disease pathology. The pharmacological chaperone (PC) DGJ (1-deoxygalactonojirimycin) binds and stabilizes α-Gal A, increasing enzyme levels in cultured cells and in vivo. The ability of DGJ to reduce GL-3 in vivo was investigated using transgenic (Tg) mice that express a mutant form of human α-Gal A (R301Q) on a knockout background (Tg/KO), which leads to GL-3 accumulation in disease-relevant tissues. Four-week daily oral administration of DGJ to Tg/KO mice resulted in significant and dose-dependent increases in α-Gal A activity, with concomitant GL-3 reduction in skin, heart, kidney, brain, and plasma; 24-week administration resulted in even greater reductions. Compared to daily administration, less frequent DGJ administration, including repeated cycles of 4 days with DGJ followed by 3 days without or every other day with DGJ, resulted in even greater GL-3 reductions that were comparable to those obtained with Fabrazyme. Collectively, these data indicate that oral administration of DGJ increases mutant α-Gal A activity and reduces GL-3 in disease-relevant tissues in Tg/KO mice, and thus merits further evaluation as a treatment for Fabry disease. Fabry disease is an X-linked lysosomal storage disorder caused by a deficiency in α-galactosidase A (α-Gal A) activity and subsequent accumulation of the substrate globotriaosylceramide (GL-3), which contributes to disease pathology. The pharmacological chaperone (PC) DGJ (1-deoxygalactonojirimycin) binds and stabilizes α-Gal A, increasing enzyme levels in cultured cells and in vivo. The ability of DGJ to reduce GL-3 in vivo was investigated using transgenic (Tg) mice that express a mutant form of human α-Gal A (R301Q) on a knockout background (Tg/KO), which leads to GL-3 accumulation in disease-relevant tissues. Four-week daily oral administration of DGJ to Tg/KO mice resulted in significant and dose-dependent increases in α-Gal A activity, with concomitant GL-3 reduction in skin, heart, kidney, brain, and plasma; 24-week administration resulted in even greater reductions. Compared to daily administration, less frequent DGJ administration, including repeated cycles of 4 days with DGJ followed by 3 days without or every other day with DGJ, resulted in even greater GL-3 reductions that were comparable to those obtained with Fabrazyme. Collectively, these data indicate that oral administration of DGJ increases mutant α-Gal A activity and reduces GL-3 in disease-relevant tissues in Tg/KO mice, and thus merits further evaluation as a treatment for Fabry disease." @default.
• W2020681444 created "2016-06-24" @default.
• W2020681444 creator A5003778691 @default.
• W2020681444 creator A5019427228 @default.
• W2020681444 creator A5034231492 @default.
• W2020681444 creator A5034658305 @default.
• W2020681444 creator A5035296804 @default.
• W2020681444 creator A5036101754 @default.
• W2020681444 creator A5036564166 @default.
• W2020681444 creator A5051476563 @default.
• W2020681444 creator A5051530258 @default.
• W2020681444 creator A5060777158 @default.
• W2020681444 creator A5088971653 @default.
• W2020681444 creator A5090900773 @default.
• W2020681444 creator A5091429164 @default.
• W2020681444 date "2010-01-01" @default.
• W2020681444 modified "2023-09-25" @default.
• W2020681444 title "The Pharmacological Chaperone 1-Deoxygalactonojirimycin Reduces Tissue Globotriaosylceramide Levels in a Mouse Model of Fabry Disease" @default.
• W2020681444 cites W1544162036 @default.
• W2020681444 cites W1568892768 @default.
• W2020681444 cites W1595555227 @default.
• W2020681444 cites W1597854169 @default.
• W2020681444 cites W1758125525 @default.
• W2020681444 cites W1965705234 @default.
• W2020681444 cites W1975365119 @default.
• W2020681444 cites W1980743876 @default.
• W2020681444 cites W1986236593 @default.
• W2020681444 cites W1991968375 @default.
• W2020681444 cites W1998963271 @default.
• W2020681444 cites W2006892813 @default.
• W2020681444 cites W2010595044 @default.
• W2020681444 cites W2011709758 @default.
• W2020681444 cites W2015300328 @default.
• W2020681444 cites W2016666007 @default.
• W2020681444 cites W2022185139 @default.
• W2020681444 cites W2022356406 @default.
• W2020681444 cites W2026507072 @default.
• W2020681444 cites W2037116242 @default.
• W2020681444 cites W2040321992 @default.
• W2020681444 cites W2042318626 @default.
• W2020681444 cites W2042609729 @default.
• W2020681444 cites W2057261483 @default.
• W2020681444 cites W2058754026 @default.
• W2020681444 cites W2071207794 @default.
• W2020681444 cites W2079316384 @default.
• W2020681444 cites W2082543317 @default.
• W2020681444 cites W2087017999 @default.
• W2020681444 cites W2088200158 @default.
• W2020681444 cites W2091164561 @default.
• W2020681444 cites W2092976540 @default.
• W2020681444 cites W2101425200 @default.
• W2020681444 cites W2101510401 @default.
• W2020681444 cites W2126269101 @default.
• W2020681444 cites W2137098232 @default.
• W2020681444 cites W2137603650 @default.
• W2020681444 cites W2147001430 @default.
• W2020681444 cites W2151653841 @default.
• W2020681444 cites W2157481090 @default.
• W2020681444 cites W2160437427 @default.
• W2020681444 cites W2313827278 @default.
• W2020681444 cites W2321507369 @default.
• W2020681444 cites W2328023011 @default.
• W2020681444 cites W2332862830 @default.
• W2020681444 cites W4234019467 @default.
• W2020681444 doi "https://doi.org/10.1038/mt.2009.220" @default.
• W2020681444 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2839206" @default.
• W2020681444 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19773742" @default.
• W2020681444 hasPublicationYear "2010" @default.
• W2020681444 type Work @default.
• W2020681444 sameAs 2020681444 @default.
• W2020681444 citedByCount "118" @default.
• W2020681444 countsByYear W20206814442012 @default.
• W2020681444 countsByYear W20206814442013 @default.
• W2020681444 countsByYear W20206814442014 @default.
• W2020681444 countsByYear W20206814442015 @default.
• W2020681444 countsByYear W20206814442016 @default.
• W2020681444 countsByYear W20206814442017 @default.
• W2020681444 countsByYear W20206814442018 @default.
• W2020681444 countsByYear W20206814442019 @default.
• W2020681444 countsByYear W20206814442020 @default.
• W2020681444 countsByYear W20206814442021 @default.
• W2020681444 countsByYear W20206814442022 @default.
• W2020681444 countsByYear W20206814442023 @default.
• W2020681444 crossrefType "journal-article" @default.
• W2020681444 hasAuthorship W2020681444A5003778691 @default.
• W2020681444 hasAuthorship W2020681444A5019427228 @default.
• W2020681444 hasAuthorship W2020681444A5034231492 @default.
• W2020681444 hasAuthorship W2020681444A5034658305 @default.
• W2020681444 hasAuthorship W2020681444A5035296804 @default.
• W2020681444 hasAuthorship W2020681444A5036101754 @default.
• W2020681444 hasAuthorship W2020681444A5036564166 @default.
• W2020681444 hasAuthorship W2020681444A5051476563 @default.
• W2020681444 hasAuthorship W2020681444A5051530258 @default.
• W2020681444 hasAuthorship W2020681444A5060777158 @default.
• W2020681444 hasAuthorship W2020681444A5088971653 @default.
• W2020681444 hasAuthorship W2020681444A5090900773 @default.
• W2020681444 hasAuthorship W2020681444A5091429164 @default.
• W2020681444 hasBestOaLocation W20206814441 @default.

• next